Cipla Limited has announced an additional investment of EUR 3 million in Ethris GmbH, further strengthening its involvement in the mRNA technology sector. This move follows an initial investment of EUR 15 million in 2022 and underscores Cipla’s commitment to advancing mRNA-based treatments, particularly for patients in emerging markets. Ethris, recognized as a leader in […]
In a strategic move poised to reshape the landscape of Central Nervous System (CNS) medication accessibility in India, Sanofi India Limited (SIL) and Cipla Limited today unveiled their exclusive partnership. This collaboration focuses on the distribution and promotion of Sanofi India’s CNS product range, including the renowned anti-epileptic medication, Frisium. Under the terms of the […]
In an important safety announcement, Cipla Limited revealed that its wholly-owned subsidiary, InvaGen Pharmaceuticals Inc., based in the USA, is conducting a voluntary recall of a specific lot of Vigabatrin for Oral Solution, USP 500mg. This decision to recall was made due to the discovery of seal integrity issues, which have led to the leakage […]